Skip to main content

 9S6Y | pdb_00009s6y

CryoEM structure of WIV1 spike monomer in complex with neutralizing antibody V1WT_06


Experimental Data Snapshot

  • Method: ELECTRON MICROSCOPY
  • Resolution: 3.98 Å
  • Aggregation State: PARTICLE 
  • Reconstruction Method: SINGLE PARTICLE 

Starting Model: experimental
View more details

wwPDB Validation 3D Report Full Report

Validation slider image for 9S6Y

This is version 1.1 of the entry. See complete history. 

Literature

Targeting of conserved spike epitopes enables broad antibody neutralisation of diverse bat sarbecoviruses.

Upadhyay, A., Seow, J., Alguel, Y., Newman, J., Thakur, N., Hay, A.L., Tam, J.C.H., Nans, A., Orton, R.J., Bailey, D., Cherepanov, P., Doores, K.J.

(2026) PLoS Biol 24: e3003882-e3003882

  • DOI: https://doi.org/10.1371/journal.pbio.3003882
  • Primary Citation Related Structures: 
    9S67, 9S6Q, 9S6Y

  • PubMed Abstract: 

    The continuing evolution of SARS-CoV-2 variants of concern, and the increasing spillover potential of sarbecoviruses into the human population presents an important and urgent need to discover cross-reactive monoclonal antibodies (mAbs) for future therapeutic use and identify conserved neutralising epitopes that can be used for rationale design of broadly protective sarbecovirus vaccines. Here we study the neutralising epitopes on WIV-1 Spike of three mAbs that confer broad sarbecovirus and SARS-CoV-2 variant neutralisation, including XEC, JN.1, and XFG. mAb V1WT_06 binds a highly conserved RBD site V epitope that is mediated by the heavy chain alone. V1WT_06 contact residues are highly conserved in circulating viruses suggesting that the epitope is evolutionarily and functionally constrained. mAbs V1WT_41 and VA14_26 bind overlapping RBD class 4 epitopes with differing angles of approach that impact on the degree of ACE2 competition. We show that neutralisation by these mAbs is maintained when virus entry is via Japanese horseshoe bat and Halcyon horseshoe bat ACE2s. These mAbs are ideal candidates for therapeutic antibody development and inform the rational design of pan-betacoronavirus vaccines.


  • Organizational Affiliation: 
    • Department of Infectious Diseases, School of Immunology & Microbial Sciences, King's College London, London, United Kingdom.

Macromolecule Content 

  • Total Structure Weight: 189.57 kDa 
  • Atom Count: 7,988 
  • Modeled Residue Count: 1,015 
  • Deposited Residue Count: 1,709 
  • Unique protein chains: 3

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
V1WT_06 Antibody Light Chain220Homo sapiensMutation(s): 0 
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
Sequence Annotations
Expand
Reference Sequence
Find similar proteins by:|  3D Structure
Entity ID: 2
MoleculeChains  Sequence LengthOrganismDetailsImage
V1WT_06 Antibody Heavy Chain250Homo sapiensMutation(s): 0 
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
Sequence Annotations
Expand
Reference Sequence
Find similar proteins by:|  3D Structure
Entity ID: 3
MoleculeChains  Sequence LengthOrganismDetailsImage
Spike glycoprotein1,239Bat SARS-like coronavirus WIV1Mutation(s): 3 
UniProt
Find proteins for U5WI05 (Bat SARS-like coronavirus WIV1)
Explore U5WI05 
Go to UniProtKB:  U5WI05
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupU5WI05
Glycosylation
Glycosylation Sites: 6
Sequence Annotations
Expand
Reference Sequence

Experimental Data & Validation

Experimental Data

  • Method: ELECTRON MICROSCOPY
  • Resolution: 3.98 Å
  • Aggregation State: PARTICLE 
  • Reconstruction Method: SINGLE PARTICLE 
EM Software:
TaskSoftware PackageVersion
MODEL REFINEMENTPHENIX1.21.2_5419
RECONSTRUCTIONcryoSPARC4.6.2

Structure Validation

View Full Validation Report



Entry History 

& Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Wellcome TrustUnited KingdomCC2058
Medical Research Council (MRC, United Kingdom)United KingdomCC2058
Cancer Research UKUnited KingdomCC2058

Revision History  (Full details and data files)

  • Version 1.0: 2026-07-08
    Type: Initial release
  • Version 1.1: 2026-10-14
    Changes: Data collection, Database references